Article Text

Download PDFPDF

4CPS-062 Patients with darunavir/cobicistat/emtricitabine/tenofovir alafenamide treatment in a third level hospital
  1. R Gracia,
  2. JM Vinuesa,
  3. I Sanjoaquin,
  4. T Salvador,
  5. MDP Pardo,
  6. MA Alcácera,
  7. A Apesteguia,
  8. MJ Crusells,
  9. S Letona,
  10. M Gimeno-Gracia
  1. Hospital Clinico Universitario Lozano Blesa, Farmacia Hospitalaria, Zaragoza, Spain


Background and importance Darunavir/cobicitat/emtricitabine/tenofovir alafenamide (DRV/c/FTC/TAF) is a new single tablet regimen for HIV. Another advantage is its coformulation with tenofovir alafenamide, and a better safety profile.

Aim and objectives To evaluate reasons for switching from one antiretroviral therapy (ART) to DRV/c/FTC/TAF, and to evaluate effectiveness, safety and patient satisfaction.

Material and methods This was an observational, descriptive, retrospective study of patients who started treatment with DRV/c/FTC/TAF and had an analytical control after the start of treatment. Variables collected: demographic, pharmacotherapeutic (reason for change to DRV/c/FTC/TAF, previous ART, number of previous active ingredients and tablets) and clinical (CD4 and CD8 lymphocytes, CD4/CD8 quotient, viral load and glomerular filtrate prior to and a median of 105 days after starting treatment). Satisfaction with ART was measured at 5 months using the ESTAR questionnaire (developed in Spanish based on the English language version of the HIV treatment satisfaction questionnaire (HIVTSQ)), with scores ranging from 0 to 60 points.

Results There were 38 patients (median age 50.5 years; 66.7% women) who initiated DRV/c/FTC/TAF. Three patients were not included: two naive and one who discontinued after a month due to intolerance. The previous ART was protease inhibitor/potentiator (PI/p) with two nucleotide analogue reverse transcriptase inhibitors (2NRTI) in 54.3% of patients, PI/p in 11.4%, integrase inhibitor (INSTI) with NRTI in 11.4% and 22.9% other. Patients switched from tenofovir diproxyl fumarate (TDF) to TAF (45.7%). Patients changed from an average of 2.57 active principles daily to 3, and from 1.78 tablets to 1.

Reasons for change were renal in 40%, CD4 decrease I 8.6%, renal and bone in 8.6%, simplification and lack of adherence in 8.6% and other in 34.2%. Median CD4 changed from 505 to 684; median CD8 from 692 to 764; and median CD4/CD8 from 0.66 to 0.69. Undetectable viral load remained stable in 97.7% of patients and glomerular filtrate in 94.3%. Scores in the ESTAR questionnaire were higher than 50 in 80% of patients.

Conclusion and relevance In daily practice, DRV/c/FTC/TAF was used in most cases to prevent damage to renal function. DRV/c/FTC/TAF is an effective and safe treatment which maintains viral load and glomerular filtrate. Patient satisfaction with the treatment was excellent.

References and/or acknowledgements No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.